Literature DB >> 25378784

Intravenous immunoglobulin in pediatrics: A review.

A N Prasad1, Sanjay Chaudhary1.   

Abstract

There has been a rapid expansion of the use of intravenous immunoglobulin (IVIG) for an ever-growing number of conditions. IVIG is used at a 'replacement dose' (400-600 mg/kg/month) in antibody deficiencies and is used at a high dose (2 g/kg) as an 'immunomodulatory' agent in an increasing number of immune and inflammatory disorders.(1) The limitations for IVIG are the cost of the preparation and the need for intravenous infusions. Due to the cost, shortages and growing use of IVIG there have been attempts to develop evidence-based guidelines for the use of IVIG in a wide variety of immune disorders in children and neonates. This commentary provides the recommendations and recent publication regarding the use of IVIG in various conditions in children.

Entities:  

Keywords:  Agammaglobulinemia; Autoimmune disorder; Immunoglobulin

Year:  2013        PMID: 25378784      PMCID: PMC4213893          DOI: 10.1016/j.mjafi.2013.05.011

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  16 in total

1.  Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions.

Authors:  Paula Robinson; David Anderson; Melissa Brouwers; Thomas E Feasby; Heather Hume
Journal:  Transfus Med Rev       Date:  2007-04

2.  Advances in the use of IVIg in neurological disorders.

Authors:  Richard Hughes
Journal:  J Neurol       Date:  2008-07       Impact factor: 4.849

Review 3.  Advances in the understanding of the mechanism of action of IVIg.

Authors:  Hans-Peter Hartung
Journal:  J Neurol       Date:  2008-07       Impact factor: 4.849

4.  Agammaglobulinemia.

Authors:  O C BRUTON
Journal:  Pediatrics       Date:  1952-06       Impact factor: 7.124

5.  Case report: acute renal failure after administering intravenous immunoglobulin.

Authors:  Aaron Graumann; Edward T Zawada
Journal:  Postgrad Med       Date:  2010-03       Impact factor: 3.840

Review 6.  Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.

Authors:  Jordan S Orange; Elham M Hossny; Catherine R Weiler; Mark Ballow; Melvin Berger; Francisco A Bonilla; Rebecca Buckley; Javier Chinen; Yehia El-Gamal; Bruce D Mazer; Robert P Nelson; Dhavalkumar D Patel; Elizabeth Secord; Ricardo U Sorensen; Richard L Wasserman; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol       Date:  2006-04       Impact factor: 10.793

7.  Appropriate uses of human immunoglobulin in clinical practice: memorandum from an IUIS/WHO meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

8.  Intravenous IgG: biological modulating molecules.

Authors:  G Luzi; F Bongiorno; S Paparo Barbaro; G Bruno
Journal:  J Biol Regul Homeost Agents       Date:  2009 Jan-Mar       Impact factor: 1.711

Review 9.  High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases.

Authors:  Norito Ishii; Takashi Hashimoto; Detlef Zillikens; Ralf J Ludwig
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 10.  Intravenous immunoglobulins: evolution of commercial IVIG preparations.

Authors:  John A Hooper
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479

View more
  1 in total

1.  Safety evaluation of intravenous immunoglobulin in pediatric patients: a retrospective, 1-year observational study.

Authors:  Reem Elajez; Asmaa Ezzeldin; Hossamaldein Gaber
Journal:  Ther Adv Drug Saf       Date:  2019-10-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.